Imre has made two key leadership appointments strengthening a historically strong Client Experience (CX) practice. This comes as the brand engagement agency continues its aim at increasing agency-of-record assignments among healthcare and specialty pharmaceutical brands.
The promotion demonstrates The Bloc’s ongoing commitment to growth and innovation in the European health communications market.
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.
In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor agonists are 14% less likely to progress to cirrhosis.
According to GlobalData’s Pharmaceutical Intelligence Center, as of September 16, in Japan there are 14 gene therapies in the preclinical stage of development targeting eight different therapy areas with a significant focus on oncology, ophthalmology, hematological disorders, and the central nervous system.
The trial, involving 586 patients, tested the drug against chemotherapy in patients with non-small cell lung cancer (NSCLC) who had a specific gene mutation leading to abnormal cell growth.